Skip to main content

Table 1 Patient characteristics at screening

From: Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications

Characteristic

MDD

(n = 25)

Schizophrenia

(n = 17)

Total Patients

(N = 42)

Sex, n (%)

   

 Male

9 (36)

11 (65)

20 (48)

 Female

16 (64)

6 (35)

22 (52)

Age, years

   

 Mean (range)

46.4 (23–70)

45.5 (25–59)

46.0 (23–70)

Race/ethnicity,a n (%)

   

 White

20 (80)

9 (53)

29 (69)

 African American

3 (12)

8 (47)

11 (26)

 Asian

1 (4)

0 (0)

1 (2)

 Hispanic/Latino

1 (4)

1 (6)

2 (5)

 Mixed race

0 (0)

1 (6)

1 (2)

Current atypical medications, n (%)b

   

 Quetiapine

6 (24)

2 (12)

8 (19)

 Aripiprazole

6 (24)

2 (12)

8 (19)

 Risperidone

3 (12)

4 (24)

7 (17)

 Olanzapine

0 (0)

4 (24)

4 (10)

 Lurasidone

3 (12)

2 (12)

5 (12)

 Clozapine

1 (4)

2 (12)

3 (7)

 Ziprasidone

2 (8)

1 (6)

3 (7)

 Paliperidone

0 (0)

1 (6)

1 (2)

 Fluphenazine

0 (0)

1 (6)

1 (2)

 Asenapine

0 (0)

1 (6)

1 (2)

  1. a Participants could report more than 1 race
  2. b Total may not equal 100%. Four patients with schizophrenia and one patient with MDD reported using more than one AAP, and four patients with MDD and 2 patients with schizophrenia had a recent history of AAP use but were not currently using an AAP at screening. Each medication listed may include reference to 1 or more brand names, the chemical or generic name, and/or different formulations